Drugs / NKT cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02619058 | Oct 2015 → Oct 2016 | melanoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01801852 | Jan 2013 → May 2016 | breast cancer, colon carcinoma, glioma, hepatocellular carcinoma +3 | Chinese PLA General Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2024-07-02 | GRI Bio Operations, Inc. | Results GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine gribio.com ↗
Data demonstrates that NKT cells are activated in airways in IPF patients and inhibition of type 1 invariant NKT (iNKT) cell activity can ameliorate bleomycin-induced pulmonary fibrosis in mice |
| 2023-10-19 | GRI Bio Operations, Inc. | Results GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference gribio.com ↗
Findings demonstrate that the number of NKT cells positively correlates with the number of airway macrophages in IPF patients |
| 2023-10-05 | GRI Bio Operations, Inc. | Results GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions gribio.com ↗
The manuscript titled, “ Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis ,” has been published in Frontiers in Immunology . |
| 2023-08-07 | GRI Bio Operations, Inc. | Results GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models gribio.com ↗
Oral administration of type 2 NKT cell agonists have been observed to inhibit animal models of lupus nephritis, proteinuria, and to significantly improve overall survival in these animal models. |
| 2020-09-14 | Lava Therapeutics | Results LAVA Therapeutics, Amsterdam UMC and Monash University Announce Publication of a Novel Cancer Immunotherapy Approach in Nature Cancer lavatherapeutics.com ↗
Preclinical research through the companies’ collaboration demonstrates that a CD1d-NKT cell targeting antibody resulted in significant activation of NKT cells and the subsequent killing of CD1d-expressing tumor cells in multiple tumor samples, including multiple myeloma and acute myeloid leukemia. |
All press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKT cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02619058 ↗ |
| Known as | natural killer T (NKT) cells | “A randomized controlled trial on the efficacy and safety of autologous natural killer T (NKT) cells infusion treatment in advanced cancer.” NCT01801852 ↗ |
| Modality | Cell therapy | “natural killer T (NKT) cell-based autologous adoptive immunotherapy” NCT01801852 ↗ |
| Route | Intravenous | “intravenous administration of autologous NKT cells” NCT02619058 ↗ |